Polpharma is the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. The company actively operates in the markets of Central and Eastern Europe, the Caucasus and Central Asia. It is among the top 25 generic drug manufacturers in the world, with sales of USD 1 billion per year.
Polpharma employs more than 7,500 people in Poland and on international markets. It has seven manufacturing plants in Poland, Russia and Kazakhstan, and six research and development centers. Polpharma Group’s portfolio includes about 600 products, and another 200 in pipeline. The company invests in the field of biological drugs: biosimilars and biobetters. It is also one of the largest Polish manufacturers of active pharmaceutical ingredients (APIs), which compete successfully in the markets of the EU and the US.